Abstract
In genomics research, pathways that lead to disease and the role of drugs in these pathways are being unravelled at a high rate. In this paper ethical and social challenges related to pharmacogenomics research are discussed as well as clinical applications. In research, ethical thinking evolves due to the fast pace of research. Genome-wide association studies trying to identify genes that contribute a small risk to common diseases can only be performed on an international scale. Meanwhile, it is becoming more and more clear that genomic information is hard to hide. Thus the traditional promise in research that privacy will be protected appears to be less realistic. Nowadays, adequate information (veracity) and protection against potential risks of discrimination based on predictive medical information is required. A new balance needs to be found. In the clinic, different ethical and social challenges become apparent. The promise to improve diagnosis, treatment and prevention is genuine, but many potentially useful applications do not reach the bedside. There is a need for both translation and for assessment of evidence if “do good and do not harm” is to be taken seriously. In addition, sustainable use of pharmacogenetic knowledge holds promises for developed and developing countries but these promises will only materialize if evidence is built, translated into guidelines, incorporated into education, implemented in pharmacy databases, and evaluated. While translational research in health care progresses slowly, direct-to-consumer testing is being implemented rapidly. International validated quality criteria should apply both to health care and to this commercial field.
Keywords: Pharmacogenomics, ethics, privacy, veracity, informed consent, anti-discrimination legislation, translation research, implementation
Current Pharmaceutical Design
Title: Ethical and Social Issues in Pharmacogenomics Testing
Volume: 16 Issue: 2
Author(s): S. J.H. Vijverberg, T. Pieters and M. C. Cornel
Affiliation:
Keywords: Pharmacogenomics, ethics, privacy, veracity, informed consent, anti-discrimination legislation, translation research, implementation
Abstract: In genomics research, pathways that lead to disease and the role of drugs in these pathways are being unravelled at a high rate. In this paper ethical and social challenges related to pharmacogenomics research are discussed as well as clinical applications. In research, ethical thinking evolves due to the fast pace of research. Genome-wide association studies trying to identify genes that contribute a small risk to common diseases can only be performed on an international scale. Meanwhile, it is becoming more and more clear that genomic information is hard to hide. Thus the traditional promise in research that privacy will be protected appears to be less realistic. Nowadays, adequate information (veracity) and protection against potential risks of discrimination based on predictive medical information is required. A new balance needs to be found. In the clinic, different ethical and social challenges become apparent. The promise to improve diagnosis, treatment and prevention is genuine, but many potentially useful applications do not reach the bedside. There is a need for both translation and for assessment of evidence if “do good and do not harm” is to be taken seriously. In addition, sustainable use of pharmacogenetic knowledge holds promises for developed and developing countries but these promises will only materialize if evidence is built, translated into guidelines, incorporated into education, implemented in pharmacy databases, and evaluated. While translational research in health care progresses slowly, direct-to-consumer testing is being implemented rapidly. International validated quality criteria should apply both to health care and to this commercial field.
Export Options
About this article
Cite this article as:
Vijverberg J.H. S., Pieters T. and Cornel C. M., Ethical and Social Issues in Pharmacogenomics Testing, Current Pharmaceutical Design 2010; 16 (2) . https://dx.doi.org/10.2174/138161210790112700
DOI https://dx.doi.org/10.2174/138161210790112700 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Exercise and Cardiac Preconditioning Against Ischemia Reperfusion Injury
Current Cardiology Reviews Current State of Bioabsorbable Polymer-Coated Drug-Eluting Stents
Current Cardiology Reviews Therapeutic Challenges in Neuroendocrine Tumors
Anti-Cancer Agents in Medicinal Chemistry Sympathetic Activation in Hypertension and in Hypertension-Related Metabolic Disease
Current Hypertension Reviews Pathogenesis and Management of Hypertension after Kidney Transplantation
Current Hypertension Reviews Sex Differences in Clinical Outcomes of Patients with Stable Coronary Artery Disease after Percutaneous Coronary Intervention
Current Pharmaceutical Design Perinatal Heart Programming: Long-term Consequences
Current Medicinal Chemistry Downregulation of Hepatic Carbonyl Reductase Type 1 in End-Stage Renal Disease
Drug Metabolism Letters Platelet-Derived Chemokines in Atherogenesis: What’s New?
Current Vascular Pharmacology Aliskiren, a Direct Renin Inhibitor, in Clinical Practice: A New Approach in the Treatment of Hypertension
Current Vascular Pharmacology Use of Peripheral Blood Stem Cells in Tissue Engineering
Current Tissue Engineering (Discontinued) Chemokines and Atherosclerotic Plaque Progression: Towards Therapeutic Targeting?
Current Pharmaceutical Design Pleiotropic Actions of PPARg Activators Thiazolidinediones in Cardiovascular Diseases
Current Pharmaceutical Design Barbituric Acids in Organic Transformations, An Outlook to the Reaction Media
Mini-Reviews in Organic Chemistry Aquaretic Agents: Whats Beyond the Treatment of Hyponatremia?
Current Pharmaceutical Design Pharmacogenomic Considerations in the Treatment of the Pediatric Cardiomyopathy Called Barth Syndrome
Recent Patents on Biotechnology Chemoprevention with Phytonutrients and Microalgae Products in Chronic Inflammation and Colon Cancer
Current Pharmaceutical Design Decreasing Arterial Aging by Controlling Blood Pressure Levels and Hypertension: A Step Forward
Current Vascular Pharmacology Heme Oxygenase-1/Carbon Monoxide: Novel Therapeutic Strategies in Critical Care Medicine
Current Drug Targets Cyclotron Production of PET Radiometals in Liquid Targets: Aspects and Prospects
Current Radiopharmaceuticals